Compass sued Zillow in June over its listing access standards, which threatened to ban listings that were not uploaded to its platform within 24 hours of being publicly marketed. Last month, a judge ...

Property brokerage Compass on Wednesday dropped its lawsuit against Zillow, ending a legal clash over how home listings can be marketed online. For the past few years, Compass — now the largest real ...

Brokerage Compass dropped its lawsuit against Zillow after the listings giant said it would allow some pre-marketed homes on its platform, ending a multi-month fight between two real estate giants ...

What You Need to Know About the New 2026 Jeep Compass - Find the best Jeep Compass deals! The Jeep brand is known for crafting vehicles that excel on fire roads. The Compass is the most affordable ...

What does the Golden Compass do? If you've just started Act 2 and you're offered the Golden Compass as a helping hand to get you started, here's what you can expect from the item and why you should ...

Compass, the largest residential real estate brokerage in the United States by sales volume, plans to lay off 110 employees in Madison in 2026. The company filed a WARN notice with the New Jersey ...

Compass’ fourth-quarter earnings call this week came with more than bottom-line metrics. The company announced a three-year partnership with Rocket and Redfin. The “strategic alliance,” as Compass ...

Compass International Holdings (CIH), the parent company of real estate brokerage Compass, is teaming up with Rocket Companies and Redfin to display its Compass Coming Soon listings for Redfin’s 60 ...

Compass Coffee, the beleaguered D.C.-based chain, has a new owner. Elizabeth L. Gunn, a U.S. bankruptcy judge for the District of Columbia, approved the sale Thursday to London-based giant Caffè Nero, ...

Kanen bought 1,573,950 Compass shares; estimated trade size $14.36 million based on quarterly average price. Quarter-end Compass position value rose by $29.11 million, reflecting both trading and ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...